A2 Biotherapeutics

A2 Biotherapeutics is pioneering a differentiated approach to cell therapy with its Tmod™ platform, which uses a dual-signal 'activator/blocker' system to selectively target tumor cells based on genetic losses common in cancer. Founded in 2018, the private company is advancing a pipeline of autologous and allogeneic CAR T-cell therapies into clinical trials for solid tumors, a major unmet need. With strategic in-house manufacturing capabilities and an experienced leadership team, A2 Bio aims to overcome the toxicity limitations of current cell therapies and unlock new targets in oncology.

Tmod™ platform: a dual-receptor logic-gated cell engineering system for T-cell therapies. It uses an 'activator' to target tumor-associated antigens and a 'blocker' to recognize protector antigens lost on tumor cells (via Loss of Heterozygosity), enabling precise tumor cell killing while sparing healthy tissues.

A2 Bio competes in the crowded solid tumor cell therapy space against companies developing alternative CAR-T designs, TCR therapies, TILs, and other logic-gated systems (e.g., from companies like Affimed, Triumvira). Its key differentiator is the specific exploitation of LOH for selectivity, a mechanism not widely employed by competitors.